Noval hexavalent recombinant protein vaccine

Noval hexavalent recombinant protein vaccine is a vaccine under development for monkeypox. It is a hexavalent recombinant protein vaccine, meaning it likely contains six different recombinant proteins from the monkeypox virus designed to elicit an immune response. The vaccine is being developed by Bowen Therapeutics Inc., which was acquired by UTime Limited, a mobile device company strategically expanding into the global vaccine market. UTime Limited is managing the ongoing clinical trials and future development with the goal of expediting the FDA registration process to address the global need for an effective monkeypox vaccine.